Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Roche, Mylan Settle Patent Case Over Drug Xeloda

Roche Holding AG, the Swiss drugmaker, settled patent litigation with generic drugmaker Mylan Inc. and reached a license agreement over the cancer medicine Xeloda, Mylan said today in a statement.

The confidential settlement, filed in federal court in Newark, New Jersey, resolves a 2009 lawsuit in which Roche claimed Mylan sought to market a generic version of Xeloda before its patent expired. The drug, which had U.S. sales of $570 million in the 12 months ending June 30, is used to treat metastatic breast and colorectal cancers.

The agreement is subject to review by the U.S. Justice Department and the Federal Trade Commission, according to Mylan, based in Canonsburg, Pennsylvania.

The case is Hoffman-LaRoche Inc. v. Mylan Inc., 09-cv-1692, U.S. District Court, District of New Jersey (Newark).

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.